Targeting aldose reductase for the treatment of cancer

R. Tammali, Satish Srivastava, Kota Ramana

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

It is strongly established by numerous studies that oxidative stress-induced inflammation is one of the major causative agents in a variety of cancers. Various factors such as bacterial, viral, parasitic infections, chemical irritants, carcinogens are involved in the initiation of oxidative stress-mediated inflammation. Chronic and persistent inflammation promotes the formation of cancerous tumors. Recent investigations strongly suggest that aldose reductase [AR; AKR1B1], a member of aldo-keto reductase superfamily of proteins, is the mediator of inflammatory signals induced by growth factors, cytokines, chemokines, carcinogens etc. Further, AR reduced product(s) of lipid derived aldehydes and their metabolites such as glutathionyl 1,4-dihydroxynonanol (GS-DHN) have been shown to be involved in the activation of transcription factors such as NF-κB and AP-1 which transcribe the genes of inflammatory cytokines. The increased inflammatory cytokines and growth factors promote cell proliferation, a main feature involved in the tumorigenesis process. Inhibition of AR has been shown to prevent cancer cell growth in vitro and in vivo models. In this review, we have described the possible association between AR with oxidative stress- and inflammation- initiated carcinogenesis. A thorough understanding of the role of AR in the inflammation-associated cancers could lead to the use of AR inhibitors as novel chemotherapeutic agents against cancer.

Original languageEnglish (US)
Pages (from-to)560-571
Number of pages12
JournalCurrent Cancer Drug Targets
Volume11
Issue number5
StatePublished - Jun 2011

Fingerprint

Aldehyde Reductase
Inflammation
Oxidative Stress
Neoplasms
Cytokines
Carcinogens
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Parasitic Diseases
Irritants
Transcription Factor AP-1
Virus Diseases
Chemokines
Aldehydes
Transcription Factors
Cell Proliferation
Lipids
Growth
Genes
Proteins

Keywords

  • Aldose reductase
  • Cancer and NF-κB
  • Inflammation
  • Oxidative stress

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Targeting aldose reductase for the treatment of cancer. / Tammali, R.; Srivastava, Satish; Ramana, Kota.

In: Current Cancer Drug Targets, Vol. 11, No. 5, 06.2011, p. 560-571.

Research output: Contribution to journalArticle

Tammali, R, Srivastava, S & Ramana, K 2011, 'Targeting aldose reductase for the treatment of cancer', Current Cancer Drug Targets, vol. 11, no. 5, pp. 560-571.
Tammali, R. ; Srivastava, Satish ; Ramana, Kota. / Targeting aldose reductase for the treatment of cancer. In: Current Cancer Drug Targets. 2011 ; Vol. 11, No. 5. pp. 560-571.
@article{c0f020a04e1348ca9698ec7a42c21592,
title = "Targeting aldose reductase for the treatment of cancer",
abstract = "It is strongly established by numerous studies that oxidative stress-induced inflammation is one of the major causative agents in a variety of cancers. Various factors such as bacterial, viral, parasitic infections, chemical irritants, carcinogens are involved in the initiation of oxidative stress-mediated inflammation. Chronic and persistent inflammation promotes the formation of cancerous tumors. Recent investigations strongly suggest that aldose reductase [AR; AKR1B1], a member of aldo-keto reductase superfamily of proteins, is the mediator of inflammatory signals induced by growth factors, cytokines, chemokines, carcinogens etc. Further, AR reduced product(s) of lipid derived aldehydes and their metabolites such as glutathionyl 1,4-dihydroxynonanol (GS-DHN) have been shown to be involved in the activation of transcription factors such as NF-κB and AP-1 which transcribe the genes of inflammatory cytokines. The increased inflammatory cytokines and growth factors promote cell proliferation, a main feature involved in the tumorigenesis process. Inhibition of AR has been shown to prevent cancer cell growth in vitro and in vivo models. In this review, we have described the possible association between AR with oxidative stress- and inflammation- initiated carcinogenesis. A thorough understanding of the role of AR in the inflammation-associated cancers could lead to the use of AR inhibitors as novel chemotherapeutic agents against cancer.",
keywords = "Aldose reductase, Cancer and NF-κB, Inflammation, Oxidative stress",
author = "R. Tammali and Satish Srivastava and Kota Ramana",
year = "2011",
month = "6",
language = "English (US)",
volume = "11",
pages = "560--571",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Targeting aldose reductase for the treatment of cancer

AU - Tammali, R.

AU - Srivastava, Satish

AU - Ramana, Kota

PY - 2011/6

Y1 - 2011/6

N2 - It is strongly established by numerous studies that oxidative stress-induced inflammation is one of the major causative agents in a variety of cancers. Various factors such as bacterial, viral, parasitic infections, chemical irritants, carcinogens are involved in the initiation of oxidative stress-mediated inflammation. Chronic and persistent inflammation promotes the formation of cancerous tumors. Recent investigations strongly suggest that aldose reductase [AR; AKR1B1], a member of aldo-keto reductase superfamily of proteins, is the mediator of inflammatory signals induced by growth factors, cytokines, chemokines, carcinogens etc. Further, AR reduced product(s) of lipid derived aldehydes and their metabolites such as glutathionyl 1,4-dihydroxynonanol (GS-DHN) have been shown to be involved in the activation of transcription factors such as NF-κB and AP-1 which transcribe the genes of inflammatory cytokines. The increased inflammatory cytokines and growth factors promote cell proliferation, a main feature involved in the tumorigenesis process. Inhibition of AR has been shown to prevent cancer cell growth in vitro and in vivo models. In this review, we have described the possible association between AR with oxidative stress- and inflammation- initiated carcinogenesis. A thorough understanding of the role of AR in the inflammation-associated cancers could lead to the use of AR inhibitors as novel chemotherapeutic agents against cancer.

AB - It is strongly established by numerous studies that oxidative stress-induced inflammation is one of the major causative agents in a variety of cancers. Various factors such as bacterial, viral, parasitic infections, chemical irritants, carcinogens are involved in the initiation of oxidative stress-mediated inflammation. Chronic and persistent inflammation promotes the formation of cancerous tumors. Recent investigations strongly suggest that aldose reductase [AR; AKR1B1], a member of aldo-keto reductase superfamily of proteins, is the mediator of inflammatory signals induced by growth factors, cytokines, chemokines, carcinogens etc. Further, AR reduced product(s) of lipid derived aldehydes and their metabolites such as glutathionyl 1,4-dihydroxynonanol (GS-DHN) have been shown to be involved in the activation of transcription factors such as NF-κB and AP-1 which transcribe the genes of inflammatory cytokines. The increased inflammatory cytokines and growth factors promote cell proliferation, a main feature involved in the tumorigenesis process. Inhibition of AR has been shown to prevent cancer cell growth in vitro and in vivo models. In this review, we have described the possible association between AR with oxidative stress- and inflammation- initiated carcinogenesis. A thorough understanding of the role of AR in the inflammation-associated cancers could lead to the use of AR inhibitors as novel chemotherapeutic agents against cancer.

KW - Aldose reductase

KW - Cancer and NF-κB

KW - Inflammation

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=79958120421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958120421&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 560

EP - 571

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 5

ER -